



CIGNA

Pharmacy Services

Phone: (800)244-6224

Fax: (800)390-9745

CIGNA HealthCare Prior Authorization Form - Rituxan (rituximab) -

Notice: Failure to complete this form in its entirety may result in delayed processing or an adverse determination for insufficient information.

PROVIDER INFORMATION			PATIENT INFORMATION		
* Provider Name:			**Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed**		
Specialty:	* DEA or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* CIGNA ID:		
Office Fax:			* Date Of Birth:		
* Is your fax machine kept in a secure location? Yes <input type="checkbox"/> No <input type="checkbox"/>			* Patient Street Address:		
* May we fax our response to your office? Yes <input type="checkbox"/> No <input type="checkbox"/>					
Office Street Address:			City	State	Zip
City	State	Zip	Patient Phone:		
Medication requested:					
<input type="checkbox"/> Rituxan (rituximab) 10mg/ml vial					
Dose and Quantity:		Duration of therapy:		J-Code:	
Where will this medication be obtained?					
<input type="checkbox"/> CIGNA Tel-Drug (<i>CIGNA's nationally preferred specialty pharmacy</i>)			<input type="checkbox"/> Retail pharmacy		
<input type="checkbox"/> Prescriber's office stock (billing on a medical claim form)			<input type="checkbox"/> Home Health / Home Infusion vendor		
<input type="checkbox"/> Other (please specify):					
Diagnosis related to use (please specify):					
<input type="checkbox"/> Rheumatoid Arthritis		<input type="checkbox"/> Non-Hodgkin's Lymphoma			
<input type="checkbox"/> relapsed/refractory Waldenstrom's macroglobulinemia			<input type="checkbox"/> immune or idiopathic thrombocytopenic purpura		
<input type="checkbox"/> Relapsed/refractory chronic lymphocytic leukemia			<input type="checkbox"/> Other (please specify):		
Rheumatoid Arthritis:					
Does the patient have a history of positive clinical response to Rituxan therapy?					
<input type="checkbox"/> Yes <input type="checkbox"/> No					
Please indicate if the patient has had evidence of failure, inadequate response, intolerance or contraindication to any of the following disease-modifying anti-rheumatic drugs (DMARDs). Please check all that apply:					
<input type="checkbox"/> Methotrexate		<input type="checkbox"/> Azathioprine		<input type="checkbox"/> Gold	
<input type="checkbox"/> Penicillamine		<input type="checkbox"/> Sulfasalazine		<input type="checkbox"/> Hydroxychloroquine	
<input type="checkbox"/> Other (please specify):					
Which of the following methods was used to measure the patient's disease progression PRIOR to therapy on Rituxan? (Check all that apply):					
<input type="checkbox"/> Health Assessment Questionnaire Disease Index (HAQ-DI)			<input type="checkbox"/> Visual Analogue scale (VAS)		
<input type="checkbox"/> Likert scales of global response to pain by the patient/doctor			<input type="checkbox"/> Global Arthritis Score (GAS)		
<input type="checkbox"/> Clinical Disease Activity Index (CDAI)			<input type="checkbox"/> Simplified Disease Activity Index (SDAI)		
<input type="checkbox"/> Progression of radiographic damage of involved joints			<input type="checkbox"/> Disease Activity Scale (DAS) score		
<input type="checkbox"/> Disease Activity Score based on 28-joint evaluation (DAS28) score Disease Activity Scale (DAS) score					
<input type="checkbox"/> Elevation of ESR (> 28 mm/hr), or C-reactive protein (CRP) (2x the upper limit of normal)					
<input type="checkbox"/> Other (please specify) :					
(Continued on page 2)					

Rheumatoid Arthritis (continued):

Has the patient had inadequate response, intolerance or contraindication to any of following Tumor Necrosis Factor (TNF) Antagonists?

- Humira (adalimumab) Enbrel (etanercept) Remicade (infliximab)

If this is a request for **CONTINUED THERAPY** (after at least 16 weeks of treatment), has the patient shown positive response to treatment with Kineret based on any of the following measurements? (Check all that showed a positive response to Kineret therapy):

- | | |
|--|---|
| <input type="checkbox"/> Health Assessment Questionnaire Disease Index (HAQ-DI) | <input type="checkbox"/> Visual Analogue scale (VAS) |
| <input type="checkbox"/> Likert scales of global response to pain by the patient/doctor | <input type="checkbox"/> Global Arthritis Score (GAS) |
| <input type="checkbox"/> Clinical Disease Activity Index (CDAI) | <input type="checkbox"/> Simplified Disease Activity Index (SDAI) |
| <input type="checkbox"/> Progression of radiographic damage of involved joints | <input type="checkbox"/> Disease Activity Scale (DAS) score |
| <input type="checkbox"/> Disease Activity Score based on 28-joint evaluation (DAS28) score | <input type="checkbox"/> Disease Activity Scale (DAS) score |
| <input type="checkbox"/> At least a 20% improvement according to ACR 20% response criteria | <input type="checkbox"/> ESR or C-reactive protein (CRP) |
| <input type="checkbox"/> Other (please specify) : | |

Additional pertinent information:

**CIGNA HealthCare's coverage position on this and other medications may be viewed online at:
http://www.cigna.com/customer_care/healthcare_professional/coverage_positions**

Please fax completed form to (800)390-9745. Phone requests may be submitted by calling (800)244-6224.

Our standard response time for prescription drug coverage requests is 2-4 business days. If your request is urgent, it is important that you call Pharmacy Services to expedite the request. View our formulary on line at <http://www.cigna.com>.

V041610

"CIGNA Pharmacy Management" or "CIGNA HealthCare" refer to various operating subsidiaries of CIGNA Corporation. Products and services are provided by these subsidiaries and not by CIGNA Corporation. These subsidiaries include Connecticut General Life Insurance Company, Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., and HMO or service company subsidiaries of CIGNA Health Corporation.